Edwards Lifesciences (EW) – Research Analysts’ Recent Ratings Updates

Edwards Lifesciences (NYSE: EW) recently received a number of ratings updates from brokerages and research firms:

  • 2/8/2018 – Edwards Lifesciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $145.00 price target on the stock. According to Zacks, “Edwards Lifesciences exited the fourth quarter 2017 on a solid note. The company has witnessed growth across all segments. It also performed well on both the gross and operating margin fronts. Also, the raised 2018 revenue and earnings guidance buoys optimism. We are currently looking forward to the company’s buyout of Harpoon Medical which should significantly boost its Surgical Heart Valve Therapy portfolio. Management expects to gain traction in the ever-expanding TAVR market, based on increasing preference in favor of transcatheter aortic valve replacement as well as compelling clinical evidence, leading to strong adoption of THV therapy. However, tough competition in the cardiac devices market and reimbursement issues continue to pose challenges. Also, over the past six months, Edwards Lifesciences has underperformed the broader industry.”
  • 2/2/2018 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $162.00 price target on the stock.
  • 2/2/2018 – Edwards Lifesciences had its price target raised by analysts at JMP Securities from $135.00 to $140.00. They now have a “market outperform” rating on the stock.
  • 2/2/2018 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $155.00 price target on the stock.
  • 2/2/2018 – Edwards Lifesciences had its price target raised by analysts at Barclays PLC from $135.00 to $155.00. They now have an “overweight” rating on the stock.
  • 2/2/2018 – Edwards Lifesciences had its price target raised by analysts at Morgan Stanley from $130.00 to $138.00. They now have an “overweight” rating on the stock.
  • 2/2/2018 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $174.00 price target on the stock, up previously from $140.00.
  • 2/1/2018 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $150.00 price target on the stock.
  • 1/31/2018 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $150.00 price target on the stock.
  • 1/4/2018 – Edwards Lifesciences was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $135.00 price target on the stock, up previously from $125.00.
  • 1/3/2018 – Edwards Lifesciences is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $140.00 price target on the stock.
  • 1/2/2018 – Edwards Lifesciences was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.

Edwards Lifesciences Corp (NYSE EW) opened at $126.27 on Monday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. The firm has a market cap of $26,721.24, a price-to-earnings ratio of 43.84, a P/E/G ratio of 1.86 and a beta of 0.63. Edwards Lifesciences Corp has a 1-year low of $89.20 and a 1-year high of $138.48.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.75 EPS. research analysts forecast that Edwards Lifesciences Corp will post 4.49 earnings per share for the current fiscal year.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $116.45, for a total transaction of $617,185.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Robert W.A. Sellers sold 12,020 shares of Edwards Lifesciences stock in a transaction on Monday, February 5th. The stock was sold at an average price of $131.03, for a total transaction of $1,574,980.60. The disclosure for this sale can be found here. Insiders have sold a total of 175,940 shares of company stock worth $20,049,578 in the last 90 days. Company insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply